EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The emerging role and mechanism of HMGA2 in breast cancer

Qing Ma, Sisi Ye, Hong Liu, Yu Zhao, Wei Zhang

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05785-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Qing Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University /West China School …. Hauptthemen laut MEDLINE: HMGA2 Protein, Breast Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High mobility group AT-hook 2 (HMGA2) is a member of the non-histone chromosomal high mobility group (HMG) protein family, which participate in embryonic development and other biological processes. HMGA2 overexpression is associated with breast cancer (BC) cell growth, proliferation, metastasis, and drug resistance. Furthermore, HMGA2 expression is positively associated with poor prognosis of patients with BC, and inhibiting HMGA2 signaling can stimulate BC cell progression and metastasis. In this review, we focus on HMGA2 expression changes in BC tissues and multiple BC cell lines. Wnt/β-catenin, STAT3, CNN6, and TRAIL-R2 proteins are upstream mediators of HMGA2 that can induce BC invasion and metastasis. Moreover, microRNAs (miRNAs) can suppress BC cell growth, invasion, and metastasis by inhibiting HMGA2 expression. Furthermore, long noncoding RNAs (LncRNAs) and circular RNAs (CircRNAs) mainly regulate HMGA2 mRNA and protein expression levels by sponging miRNAs, thereby promoting BC development. Additionally, certain small molecule inhibitors can suppress BC drug resistance by reducing HMGA2 expression. Finally, we summarize findings demonstrating that HMGA2 siRNA and HMGA2 siRNA-loaded nanoliposomes can suppress BC progression and metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HMGA2 ProteinBreast NeoplasmsHumansFemaleGene Expression Regulation, NeoplasticMicroRNAsDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Breast cancerDrug resistanceHMGA2MetastasisNon-coding RNAs

Substanzen

HMGA2 ProteinMicroRNAsHMGA2 protein, human

Autor:innen und Institutionen

  • General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University /West China School of Nursing, Sichuan University, Chengdu, China.
  • Emergency Department of West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, China. zhangyijia848655@163.com.

Zitieren

APA

Ma, Q., Ye, S., Liu, H., Zhao, Y., & Zhang, W. (2024). The emerging role and mechanism of HMGA2 in breast cancer. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05785-4

Vancouver

Ma Q, Ye S, Liu H, Zhao Y, Zhang W. The emerging role and mechanism of HMGA2 in breast cancer. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05785-4

BibTeX
@article{Ma2024,
  author = {Ma, Qing and Ye, Sisi and Liu, Hong and Zhao, Yu and Zhang, Wei},
  title = {The emerging role and mechanism of HMGA2 in breast cancer},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05785-4}
}
Kostenlos starten →